The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hypertension and Heart Failure Drugs Market Research Report 2025
Synopsis
Hypertension and Heart Failure Drugs such as β-blockers, angiotensin-converting enzyme inhibitiors, angiotensin receptor blockers, aldosterone receptor blockers, hydralazine and nitrates, which have shown mortality benefit in CHF and exert antihypertensive effects, are used as first-line agents to control HTN in CHF.
The global Hypertension and Heart Failure Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Hypertension and Heart Failure Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hypertension and Heart Failure Drugs.
Report Scope
The Hypertension and Heart Failure Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hypertension and Heart Failure Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hypertension and Heart Failure Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Menarini Group
Johnson & Johnson
Lupin
Boehringer Ingelheim
Novartis
Merck & Co
AstraZeneca
Pfizer, Inc
Sanofi SA
Dr. Reddy's Laboratories
Daiichi Sankyo Company Limited
Segment by Type
Diuretics
Beta Blockers
Ace Inhibitors
Alpha Blockers
Others
Segment by Application
Men
Women
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hypertension and Heart Failure Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Hypertension and Heart Failure Drugs such as β-blockers, angiotensin-converting enzyme inhibitiors, angiotensin receptor blockers, aldosterone receptor blockers, hydralazine and nitrates, which have shown mortality benefit in CHF and exert antihypertensive effects, are used as first-line agents to control HTN in CHF.
The global Hypertension and Heart Failure Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Hypertension and Heart Failure Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hypertension and Heart Failure Drugs.
Report Scope
The Hypertension and Heart Failure Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hypertension and Heart Failure Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hypertension and Heart Failure Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Menarini Group
Johnson & Johnson
Lupin
Boehringer Ingelheim
Novartis
Merck & Co
AstraZeneca
Pfizer, Inc
Sanofi SA
Dr. Reddy's Laboratories
Daiichi Sankyo Company Limited
Segment by Type
Diuretics
Beta Blockers
Ace Inhibitors
Alpha Blockers
Others
Segment by Application
Men
Women
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hypertension and Heart Failure Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hypertension and Heart Failure Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Diuretics
1.2.3 Beta Blockers
1.2.4 Ace Inhibitors
1.2.5 Alpha Blockers
1.2.6 Others
1.3 Market by Application
1.3.1 Global Hypertension and Heart Failure Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Men
1.3.3 Women
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hypertension and Heart Failure Drugs Market Perspective (2019-2030)
2.2 Hypertension and Heart Failure Drugs Growth Trends by Region
2.2.1 Global Hypertension and Heart Failure Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Hypertension and Heart Failure Drugs Historic Market Size by Region (2019-2024)
2.2.3 Hypertension and Heart Failure Drugs Forecasted Market Size by Region (2025-2030)
2.3 Hypertension and Heart Failure Drugs Market Dynamics
2.3.1 Hypertension and Heart Failure Drugs Industry Trends
2.3.2 Hypertension and Heart Failure Drugs Market Drivers
2.3.3 Hypertension and Heart Failure Drugs Market Challenges
2.3.4 Hypertension and Heart Failure Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hypertension and Heart Failure Drugs Players by Revenue
3.1.1 Global Top Hypertension and Heart Failure Drugs Players by Revenue (2019-2024)
3.1.2 Global Hypertension and Heart Failure Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Hypertension and Heart Failure Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hypertension and Heart Failure Drugs Revenue
3.4 Global Hypertension and Heart Failure Drugs Market Concentration Ratio
3.4.1 Global Hypertension and Heart Failure Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hypertension and Heart Failure Drugs Revenue in 2023
3.5 Hypertension and Heart Failure Drugs Key Players Head office and Area Served
3.6 Key Players Hypertension and Heart Failure Drugs Product Solution and Service
3.7 Date of Enter into Hypertension and Heart Failure Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hypertension and Heart Failure Drugs Breakdown Data by Type
4.1 Global Hypertension and Heart Failure Drugs Historic Market Size by Type (2019-2024)
4.2 Global Hypertension and Heart Failure Drugs Forecasted Market Size by Type (2025-2030)
5 Hypertension and Heart Failure Drugs Breakdown Data by Application
5.1 Global Hypertension and Heart Failure Drugs Historic Market Size by Application (2019-2024)
5.2 Global Hypertension and Heart Failure Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Hypertension and Heart Failure Drugs Market Size (2019-2030)
6.2 North America Hypertension and Heart Failure Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Hypertension and Heart Failure Drugs Market Size by Country (2019-2024)
6.4 North America Hypertension and Heart Failure Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hypertension and Heart Failure Drugs Market Size (2019-2030)
7.2 Europe Hypertension and Heart Failure Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Hypertension and Heart Failure Drugs Market Size by Country (2019-2024)
7.4 Europe Hypertension and Heart Failure Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hypertension and Heart Failure Drugs Market Size (2019-2030)
8.2 Asia-Pacific Hypertension and Heart Failure Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Hypertension and Heart Failure Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Hypertension and Heart Failure Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hypertension and Heart Failure Drugs Market Size (2019-2030)
9.2 Latin America Hypertension and Heart Failure Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Hypertension and Heart Failure Drugs Market Size by Country (2019-2024)
9.4 Latin America Hypertension and Heart Failure Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hypertension and Heart Failure Drugs Market Size (2019-2030)
10.2 Middle East & Africa Hypertension and Heart Failure Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Hypertension and Heart Failure Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Hypertension and Heart Failure Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Menarini Group
11.1.1 Menarini Group Company Detail
11.1.2 Menarini Group Business Overview
11.1.3 Menarini Group Hypertension and Heart Failure Drugs Introduction
11.1.4 Menarini Group Revenue in Hypertension and Heart Failure Drugs Business (2019-2024)
11.1.5 Menarini Group Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Detail
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Hypertension and Heart Failure Drugs Introduction
11.2.4 Johnson & Johnson Revenue in Hypertension and Heart Failure Drugs Business (2019-2024)
11.2.5 Johnson & Johnson Recent Development
11.3 Lupin
11.3.1 Lupin Company Detail
11.3.2 Lupin Business Overview
11.3.3 Lupin Hypertension and Heart Failure Drugs Introduction
11.3.4 Lupin Revenue in Hypertension and Heart Failure Drugs Business (2019-2024)
11.3.5 Lupin Recent Development
11.4 Boehringer Ingelheim
11.4.1 Boehringer Ingelheim Company Detail
11.4.2 Boehringer Ingelheim Business Overview
11.4.3 Boehringer Ingelheim Hypertension and Heart Failure Drugs Introduction
11.4.4 Boehringer Ingelheim Revenue in Hypertension and Heart Failure Drugs Business (2019-2024)
11.4.5 Boehringer Ingelheim Recent Development
11.5 Novartis
11.5.1 Novartis Company Detail
11.5.2 Novartis Business Overview
11.5.3 Novartis Hypertension and Heart Failure Drugs Introduction
11.5.4 Novartis Revenue in Hypertension and Heart Failure Drugs Business (2019-2024)
11.5.5 Novartis Recent Development
11.6 Merck & Co
11.6.1 Merck & Co Company Detail
11.6.2 Merck & Co Business Overview
11.6.3 Merck & Co Hypertension and Heart Failure Drugs Introduction
11.6.4 Merck & Co Revenue in Hypertension and Heart Failure Drugs Business (2019-2024)
11.6.5 Merck & Co Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Detail
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Hypertension and Heart Failure Drugs Introduction
11.7.4 AstraZeneca Revenue in Hypertension and Heart Failure Drugs Business (2019-2024)
11.7.5 AstraZeneca Recent Development
11.8 Pfizer, Inc
11.8.1 Pfizer, Inc Company Detail
11.8.2 Pfizer, Inc Business Overview
11.8.3 Pfizer, Inc Hypertension and Heart Failure Drugs Introduction
11.8.4 Pfizer, Inc Revenue in Hypertension and Heart Failure Drugs Business (2019-2024)
11.8.5 Pfizer, Inc Recent Development
11.9 Sanofi SA
11.9.1 Sanofi SA Company Detail
11.9.2 Sanofi SA Business Overview
11.9.3 Sanofi SA Hypertension and Heart Failure Drugs Introduction
11.9.4 Sanofi SA Revenue in Hypertension and Heart Failure Drugs Business (2019-2024)
11.9.5 Sanofi SA Recent Development
11.10 Dr. Reddy's Laboratories
11.10.1 Dr. Reddy's Laboratories Company Detail
11.10.2 Dr. Reddy's Laboratories Business Overview
11.10.3 Dr. Reddy's Laboratories Hypertension and Heart Failure Drugs Introduction
11.10.4 Dr. Reddy's Laboratories Revenue in Hypertension and Heart Failure Drugs Business (2019-2024)
11.10.5 Dr. Reddy's Laboratories Recent Development
11.11 Daiichi Sankyo Company Limited
11.11.1 Daiichi Sankyo Company Limited Company Detail
11.11.2 Daiichi Sankyo Company Limited Business Overview
11.11.3 Daiichi Sankyo Company Limited Hypertension and Heart Failure Drugs Introduction
11.11.4 Daiichi Sankyo Company Limited Revenue in Hypertension and Heart Failure Drugs Business (2019-2024)
11.11.5 Daiichi Sankyo Company Limited Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
